Regulatory Strategy Modeled for Every Stage

For Early Stage Biotech

De-Risk Your First Regulatory Interaction

When resources are limited and timelines are tight, strategic mistakes are expensive.

What You’re Facing:

• First FDA meeting uncertainty

• IND-enabling program sufficiency questions

• Pathway selection ambiguity

• Budget constraints

• Pressure from investors

How Gulfstream Helps:

• Simulates likely FDA questions before meetings

• Evaluates accelerated approval feasibility early

• Identifies nonclinical or CMC gaps before submission

• Models strategic tradeoffs before committing capital

Outputs:

• FDA Question Optimization Brief

• IND Readiness Score

• Risk Heatmap

• Strategy Decision Tree

For Mid Sized Biotech

Model Marketing Application Filing Risk

As programs mature, risk becomes multi-dimensional.

What You’re Managing

• Cross-functional alignment (CMC, clinical, stats)

• Accelerated approval positioning

• Safety database sufficiency

• Submission readiness timing

• Board-level pressure

How Gulfstream Helps

• Predicts likely information requests and deficiencies

• Scores BLA / NDA / MAA readiness across modules

• Evaluates accelerated approval probability bands

• Aligns CMC risk with clinical strategy

Outputs

• Submission Readiness Scorecard

• Deficiency Risk Forecast

• Accelerated Approval Probability Analysis

• Executive Risk Summary

For Large Pharma

Portfolio Level Regulatory Intelligence

Large organizations face complexity across multiple programs and global agencies.

What You’re Managing

• Multi-asset portfolios

• Global regulatory divergence (FDA / EMA / others)

• Inspection risk

• Lifecycle commitments

• Executive oversight

How Gulfstream Helps

Compares regulatory risk across programs

• Models agency divergence scenarios

• Tracks post-approval commitments

• Provides leadership dashboards

Outputs

• Portfolio Risk Ranking

• Cross-Agency Divergence Model

• Lifecycle Commitment Tracker

• Executive Oversight Dashboard